Analysts Issue Forecasts for RARE FY2025 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will earn ($4.44) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $118.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.15) per share.

A number of other research analysts have also recently issued reports on RARE. TD Cowen raised their price objective on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 21st. HC Wainwright reiterated a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. Piper Sandler boosted their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, January 13th. Wedbush restated a “neutral” rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Finally, Wells Fargo & Company upped their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $42.94 on Wednesday. The firm has a market cap of $3.97 billion, a P/E ratio of -6.64 and a beta of 0.58. The firm’s fifty day moving average is $44.63 and its 200 day moving average is $49.59. Ultragenyx Pharmaceutical has a 52 week low of $37.02 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business’s quarterly revenue was up 42.3% on a year-over-year basis. During the same period last year, the business earned ($2.23) earnings per share.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 103.8% in the second quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock worth $76,065,000 after purchasing an additional 942,529 shares during the last quarter. Alkeon Capital Management LLC increased its holdings in Ultragenyx Pharmaceutical by 34.3% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock worth $167,301,000 after buying an additional 769,884 shares in the last quarter. Two Sigma Advisers LP raised its position in Ultragenyx Pharmaceutical by 123.4% in the 3rd quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company’s stock worth $54,872,000 after buying an additional 545,600 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $17,468,000. Finally, Ikarian Capital LLC bought a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at about $9,943,000. 97.67% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Emil D. Kakkis sold 11,727 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the sale, the chief executive officer now owns 2,183,985 shares in the company, valued at $92,229,686.55. This represents a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.